What is Amgen's UPLIZNA — total revenues?

Amgen (AMGN) reported UPLIZNA — total revenues of $262M in Q1 2026.

What does UPLIZNA — total revenues mean?

The total amount of money generated from sales of this specific drug during the period.

How do you interpret UPLIZNA — total revenues?

Increasing revenues signal successful market penetration, strong physician adoption, and effective commercial execution, while declining revenues may indicate market saturation or competitive pressure.

How does UPLIZNA — total revenues compare across companies?

Revenue performance for specialized therapeutics is typically benchmarked against peer products in the same disease category, with growth rates often compared to industry-wide specialty pharmacy trends.

Amgen AMGN UPLIZNA — Total revenues

Other product segments

Repatha

$3.02B—

Other products

$1.53B+3.6%

Prolia

$727M-33.8%

EVENITY

$562M+27.1%

TEPEZZA

$490M+28.6%

Otezla

$431M-1.4%

BLINCYTO

$415M+12.2%

Nplate

$412M+31.6%

XGEVA

$411M-27.4%

TEZSPIRE

$343M+20.4%

KYPROLIS

$330M+1.9%

ENBREL

$320M-37.3%

Aranesp

$311M-8.5%

Vectibix

$287M+7.5%

IMDELLTRA/IMDYLLTRA

$258M+219%

KRYSTEXXA

$255M+8.1%

Similar metrics at other companies

INCYOPZELURA — Total revenues

$143.02M+20.5%

UTHRNet product sales — Net Sales

$516M+16.0%

BIIBPLEGRIDY — Total Revenue

$64.3M+8.1%

BMRNNAGLAZYME — Total revenues

$130.07M+13.8%

UTHRRemodulin — Total revenues

$126.6M-8.4%

BMRNPALYNZIQ — Total revenues

$89.56M-4.0%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$182.21B+13.3%

Enterprise value$238.97B+9.9%

P/E23.4×-3.7×

P/S4.9×+0.2×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's uplizna — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's UPLIZNA — total revenues?: Amgen (AMGN) reported UPLIZNA — total revenues of $262M in Q1 2026.
What does UPLIZNA — total revenues mean?: The total amount of money generated from sales of this specific drug during the period.
How do you interpret UPLIZNA — total revenues?: Increasing revenues signal successful market penetration, strong physician adoption, and effective commercial execution, while declining revenues may indicate market saturation or competitive pressure.
How does UPLIZNA — total revenues compare across companies?: Revenue performance for specialized therapeutics is typically benchmarked against peer products in the same disease category, with growth rates often compared to industry-wide specialty pharmacy trends.